A practical reference on Albumin conjugation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Glucokinase has a lower affinity for glucose than the other hexokinases. Glucokinase changes conformation and/or function in parallel with rising glucose concentrations in the physiologically important range of 4–10 mM (72–180 mg/dL). It is half-saturated at a glucose concentration of about 8 mM (144 mg/dL). Glucokinase is not inhibited by physiological concentrations of its product, glucose-6-phosphate. This allows continued signal output (e.g., to trigger insulin release) amid significant amounts of its product. Another distinctive property of glucokinase is its moderate cooperativity with glucose, with a Hill coefficient (h) of about 1.7. These features allow it to regulate a "supply-driven" metabolic pathway. That is, the rate of reaction is driven by the supply of glucose, not by the demand for end products. Because of the cooperativity, the kinetic interaction of glucokinase with glucose does not follow classical Michaelis-Menten kinetics. Rather than a Km for glucose, it is more accurate to describe a half-saturation level S0.5, the concentration at which the enzyme is 50% saturated and active. The S0.5 and h result in an inflection of the curve enzyme activity as a function of glucose concentration at about 4 mM. In other words, at a glucose concentration of about 72 mg/dL, which is near the low end of the normal range, glucokinase activity is most sensitive to small changes in glucose concentration.
== Background == High performance liquid chromatography (HPLC) and electron ionization mass spectrometry (EIMS) are two analytical techniques that, in principle, seem to be incompatible. However, because these two approaches share a great deal of applications in the analysis of suitable molecules, typically less than 1000 u, a large effort has been devoted by the scientific community to develop a reliable, easy-to-use, and flawless interface. The first successful and commercially available device to combine EI and HPLC was designed by Willoughby and Browner in 1984. It was based on the conversion of the solute into a beam of particles, after the formation of spray droplets and the elimination of the solvent vapors through a multi-stage momentum separator. Although its efficient interfacing mechanism and a unique trait, particle beam performance was sometimes inadequate to an increasing number of new, demanding applications and was quickly replaced by a family of atmospheric pressure ionization-based interfaces (API) when they became commercially available. However, the possibility to record an EI spectrum from an HPLC application remained a challenge for a long time. The first Direct-EI prototype was first presented in 2002 and proposed an innovative approach that improved interfacing performance compared to that of particle beam and opened new opportunities for LC-MS applications.
=== Raynaud's phenomenon === Raynaud's phenomenon is frequently the first manifestation of CREST/lcSSc, preceding other symptoms by years. Stress and cold temperature induce an exaggerated vasoconstriction of the small arteries, arterioles, and thermoregulatory vessels of the skin of the digits. Clinically this manifests as a white-blue-red transition in skin color. Underlying this transition is pallor and cyanosis of the digits, followed by a reactive hyperemia as they rewarm. When extreme and frequent, this phenomenon can lead to digital ulcerations, gangrene, or amputation. Ulceration can predispose to chronic infections of the involved site.
Nelumbo nucifera is a lotus species with historical, cultural and spiritual significance. It is a sacred flower in both Hinduism and Buddhism, representing the path to spiritual awakening and enlightenment. Lotus is closely associated with Goddess Lakshmi and her consort Vishnu. In Hindu iconography, Lakshmi is shown either in seated posture or as standing on top of a lotus flower and holding lotuses in two of her four hands. Vishnu is always portrayed with a lotus in one of his hands. Lotus or Padma exemplifies the path of one who leads a dharmic life. One can stay in the darkness, trapped in the comfort of the decaying leaves and murky water or struggle to lead a dharmic life upholding righteousness, following the light and eventually liberate oneself of his/her past thereby leading a prosperous peaceful happy life. Lotus also signifies moksha. The roots of lotus plant intertwined in mud representing the cycle of life and death and the lotus flower symbolizing the serene blissful state of moksha. Lotus is also used to depict the awakening of Kundalini energy in the tantric system of Hinduism. In Hindu literature, lotus petals are used as a simile to praise the eyes of gods and goddesses. For instance, the word Kamalanayana (lotus-eyed) refers to Vishnu and it extols his eyes and praise him for being the one who holds the gaze/adoration of Kamala (Lakshmi).
4 March The Rector of Saigon University, Professor Tran Anh, was shot by VC on a motorcycle; previously he had been notified that he was on the "death list" of the "Suicide Regiment of the Saigon Youth Guard."
Sources: en.wikipedia.org
== Detection in alcoholic beverages == The concerns raised by the toxicological aspects of EC together with the low concentration levels (μg/L) found in wines, as well as the occurrence of interferences on detection, has motivated several researchers to develop new methods to determine it in wines. Several extraction and chromatographic techniques have been used, including continuous liquid–liquid extraction (LLE) with Soxhlet apparatus, derivatization with 9-xanthydrol followed by high-performance liquid chromatography (HPLC) with fluorescence detection and even LLE after derivatization, followed by gas chromatography coupled with mass spectrometry detection (GC–MS). On the other hand, the reference method set by the International Organization of Vine and Wine (OIV) uses solid phase extraction (SPE) preceding GC–MS quantification. Other methods also make use of SPE, but use gas chromatography with mass spectrometry (MDGC/MS) and liquid chromatography with tandem mass spectrometry (LC–MS/MS) for detection. Most of the methodologies found in the literature to quantify EC use gas chromatography, using LLE and SPE as extraction techniques. Nevertheless, several efforts have also been done to develop new methodologies to determine EC without using long procedures and hard-working analyses, combining precision to high sensitivity.
== History == Roadie was founded by Marc Gorlin, a co-founder of Kabbage and founder of VerticalOne and Pretty Good Privacy, as a same-day and urgent delivery company in 2014. In January 2015, Roadie launched the first consumer to consumer (C2C) version of its app with a Series A funding round of $10 million. In February, Roadie announced a partnership with Waffle House to designate its restaurants "Roadie Roadhouses", offering a neutral meeting place for drivers and senders. Drivers receive free food and drink through the partnership. In May, late-night host Jimmy Kimmel discussed the Roadie-Waffle House relationship in an opening monologue on Jimmy Kimmel Live!. Roadie's driver network expanded significantly as a result. Roadie closed a Series B round of funding in June, raising $15 million, and its first business to business (B2B) app version launched that November. In 2015, Delta Air Lines signed an agreement with Roadie to deliver mishandled luggage, becoming Roadie’s first enterprise customer. Roadie launched a pilot program with Delta at Daytona Beach International Airport. Since then, the relationship has expanded to include over 70 airports around the United States and a first mile/last mile line haul relationship with Delta Cargo. In 2017, the company signed a deal with The Home Depot, also based in Atlanta, and in February 2019, closed a Series C round of funding. In October 2019, Roadie and Delta Cargo announced a partnership to create a same-day cross-country delivery offering, DASH Door-to-Door, the first of its kind from a U.S. passenger airline.
== See also == Air-free technique – Chemistry laboratory technique Acidic oxide – Type of oxide, a.k.a. acid anhydride Base anhydride – Oxide of a chemical element from alkali- or alkaline earth metals Hydrate – Substance containing water or its constituent elements
== Incumbents == Lord Lieutenant of Anglesey – Henry Paget Lord Lieutenant of Brecknockshire and Monmouthshire – Henry Somerset, 6th Duke of Beaufort Lord Lieutenant of Caernarvonshire – Thomas Bulkeley, 7th Viscount Bulkeley Lord Lieutenant of Cardiganshire – Thomas Johnes Lord Lieutenant of Carmarthenshire – George Rice, 3rd Baron Dynevor Lord Lieutenant of Denbighshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Flintshire – Robert Grosvenor, 1st Marquess of Westminster Lord Lieutenant of Glamorgan – John Stuart, 1st Marquess of Bute Lord Lieutenant of Merionethshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Montgomeryshire – Edward Clive, 1st Earl of Powis Lord Lieutenant of Pembrokeshire – Richard Philipps, 1st Baron Milford Lord Lieutenant of Radnorshire – George Rodney, 3rd Baron Rodney Bishop of Bangor – William Cleaver (until 25 November) Bishop of Llandaff – Richard Watson Bishop of St Asaph – Samuel Horsley (until 4 October); William Cleaver (from 25 November) Bishop of St Davids – Thomas Burgess
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.